Dedicated Breast MR Imaging System Distinguishes Between Tumor and Normal Fat Tissue

Publication
Article
OncologyONCOLOGY Vol 9 No 5
Volume 9
Issue 5

he development and testing of a new method of high quality clinical fat/water separated 3D breast MR images was recently announced by Advanced NMR Systems Inc., with its subsidiary, Advanced Mammography Systems Inc.

he development and testing of a new method of high quality clinicalfat/water separated 3D breast MR images was recently announcedby Advanced NMR Systems Inc., with its subsidiary, Advanced MammographySystems Inc.

This new technique, used in conjunction with their imaging technologyfor breast diagnosis, suppresses the signal from fatty tissue,and allows MR imaging to distinguish tumor from normal fat breasttissue. In contrast, conventional nondedicated MR imaging generallycannot distinguish between tumor and normal fat breast tissue.

This new method also reduces breast imaging to under 6 minutes,according to the company, thereby increasing patient comfort.

A patent application for this technique is currently being processedfor filing. Advanced Mammography Systems Inc. has completed aprototype of its dedicated MR mammography system, and is currentlynegotiating with medical facilities for its installation. Thecompany has filed for Food and Drug Administration clearance forcommercial use of this system.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content